Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MSMZ | ISIN: US03152W1099 | Ticker-Symbol: AM6
Tradegate
31.03.25
16:09 Uhr
7,450 Euro
-0,350
-4,49 %
1-Jahres-Chart
AMICUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
AMICUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,5007,55022:00
7,4507,65022:00

Aktuelle News zur AMICUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAmicus Therapeutics (NASDAQ:FOLD) Stock Price Down 2.5% - Should You Sell?1
13.03.Amicus Therapeutics, Inc. (FOLD): Among the Stocks Under $10 With High Upside Potential3
19.02.Amicus Therapeutics files for potential mixed shelf offering2
19.02.AMICUS THERAPEUTICS, INC. - 10-K, Annual Report-
19.02.BofA cuts Amicus Therapeutics stock target to $14, keeps Buy rating4
19.02.Amicus Therapeutics beats FY topline estimates2
AMICUS THERAPEUTICS Aktie jetzt für 0€ handeln
19.02.Amicus Therapeutics, Inc.: Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates1442024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and...
► Artikel lesen
19.02.AMICUS THERAPEUTICS, INC. - 8-K, Current Report-
18.02.Amicus Therapeutics FY 2024 Earnings Preview3
10.02.Amicus Therapeutics, Inc.: Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 20252
03.02.Amicus Therapeutics, Inc.: Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium 20252
30.01.Amicus Therapeutics UK Limited: Amicus Therapeutics Launches Amicus Ignite, a Proactive Community Funding Programme for Initiatives That Support People Living With Pompe Disease274Funding of up to €20,000 (or local currency equivalent), per application, for a limited number of projects is available to organisations and projects located outside of the United States. Projects...
► Artikel lesen
17.01.Amicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside Potential3
13.01.A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts3
13.01.Amicus Therapeutics expects 2024 revenue slightly above consensus, guides 20254
13.01.AMICUS THERAPEUTICS, INC. - 8-K, Current Report-
12.01.Amicus Therapeutics, Inc.: Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook1482024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® Total Revenue Growth of 17-24% at CER Expected...
► Artikel lesen
12.11.24A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics27
12.11.24The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts5
12.11.24Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)2
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1